Ibuvit D3 2000 IU x 30 caps.

Directions for use: Use as directed by your doctor
Detailed instructions for use can be found in the leaflet included in the package.

Storage: Store at ambient temperature

Colecalciferol

Zakłady Farmaceutyczne Polpharma S.A.

Zakłady Farmaceutyczne Polpharma S.A.,
street Pelplińska 19,
83-200 Starogard Gdański,
EN

The total dose of vitamin D in patients consists of the vitamin D content of other medicinal products taken and foods rich in vitamin D consumed, as well as the vitamin produced by the body as a result of exposure to solar radiation. In Poland, sufficient exposure to sunlight is only possible in the period from May to September and requires at least 15 minutes of exposure to the sun a day from 10:00 a.m. to 3:00 p.m., with forearms and lower legs uncovered, without using creams with UV filters.Vitamin D should be used with caution in patients with impaired renal function and its effect on calcium and phosphorus levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with renal impairment treated with Ibuvit D3, parameters of calcium and phosphate metabolism should be monitored. Caution is necessary in patients receiving treatment for cardiovascular disease. Vitamin D should be used with caution in patients with sarcoidosis due to the risk of increased conversion of vitamin D to its active form. Serum and urine calcium levels should be monitored in these patients. There are no significant indications for 25(OH)D measurement in the general population. Patients taking other medications, dietary supplements containing vitamin D (cholecalciferol), calcitriol or other metabolites or analogues of vitamin D should consult a doctor before taking Ibuvit D3 to select the appropriate dose. Obese patients (adults - BMI ≥ 30 kg/m2, children, adolescents - BMI > 90th percentile) require twice the dose of vitamin D than recommended for peers with normal body weight. There is no
insufficient data on the effect of vitamin D administration on the formation of kidney stones, although such a risk is possible, especially in the case of additional calcium supplementation. The need for additional calcium supplementation should be individually considered. Calcium levels in serum and urine should be monitored.
In case of long-term use of vitamin D, especially daily doses significantly exceeding the recommended doses, calcium levels in serum and urine should be monitored and kidney function should be monitored by measuring creatinine levels. This is especially important in elderly patients and in cases of simultaneous treatment with cardiac glycosides or thiazide diuretics that reduce urinary calcium excretion.